An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages 599-613

  Moore, Nicole L ^a   Buchanan, Grant ^c   Harris, Jonathan M ^b   Selth, Luke A ^a   Bianco Miotto, Tina ^d   Hanson, Adrienne R ^a   Birrell, Stephen N ^a   Butler, Lisa M ^a   Hickey, Theresa E ^a   Tilley, Wayne D ^a  

^a University of Adelaide   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; DEXAMETHASONE; ESTROGEN; GLUTAMINE; GLYCINE; HISTIDINE; LIGAND; MEDROXYPROGESTERONE ACETATE; THREONINE; WNT PROTEIN;

AMINO ACID SUBSTITUTION; APOCRINE GLAND; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; EXON; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SET ENRICHMENT ANALYSIS; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIGAND BINDING; MOLECULAR MODEL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; APOCRINE GLANDS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MODELS, MOLECULAR; MODELS, THEORETICAL; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PARACRINE COMMUNICATION; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864414249     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0065     Document Type: Article

References (63)

1. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno M & Lanzino M 2002 Breast cancer: from estrogen to androgen receptor. Molecular and Cellular Endocrinology 193 121. (doi:10.1016/S0303-7207(02)00105-3)
2. Benjamini Y & Hochberg Y 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B 57 289-300.
3. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ & Tilley WD 1999 Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Molecular and Cellular Endocrinology 154 11-20. (doi:10.1016/S0303-7207(99)00109-4)
4. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ & Tilley WD 1995 Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 52 459-467. (doi:10.1016/0960-0760(95)00005-K)
5. Birrell SN, Butler LM, Harris JM, Buchanan G & Tilley WD 2007 Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB Journal 21 2285-2293. (doi:10.1096/fj.06-7518com)
6. Brookes DE, Zandvliet D, Watt F, Russell PJ & Molloy PL 1998 Relative activity and specificity of promoters from prostate-expressed genes. Prostate 35 18-26. (doi:10.1002/(SICI)1097-0045(19980401)35:1〈18::AID-PROS3〉3. 0.CO;2-D)
7. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR et al. 2001 Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Molecular Endocrinology 15 46-56. (doi:10.1210/me.15. 1.46)
8. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA et al. 2004 Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics 13 1677-1692. (doi:10.1093/hmg/ddh181)
9. Buchanan G, Need EF, Barrett JM, Bianco-Miotto T, Thompson VC, Butler LM, Marshall VR, Tilley WD & Coetzee GA 2011 Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Molecular and Cellular Endocrinology 342 20-31. (doi:10.1016/j.mce.2011.05.023)
10. Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C, Saint K, Lee M, Ochnik A, Yang M et al. 2006 Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology 20 1009-1024. (doi:10.1210/me.2004-0401)
11. Callewaert L, Verrijdt G, Christiaens V, Haelens A & Claessens F 2003 Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. Journal of Biological Chemistry 278 8212-8218. (doi:10.1074/jbc. M210744200)
12. Carey L, Winer E, Viale G, Cameron D & Gianni L 2010 Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews. Clinical Oncology 7 683-692. (doi:10.1038/nrclinonc.2010.154)
13. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM & Pascual-Montano A 2007 GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biology 8 R3. (doi:10.1186/gb-2007-8-1-r3)
14. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS et al. 2010 Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Research and Treatment 124 607-617. (doi:10.1007/s10549-010-0761-y)
15. Chouinard S, Pelletier G, Belanger A & Barbier O 2006 Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 147 5431-5442. (doi:10.1210/en.2006- 0229)
16. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S, Schroth GP, Seifert M et al. 2010 Estrogen receptor α controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. American Journal of Pathology 176 2113-2130. (doi:10.2353/ajpath.2010.090837)
17. Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM & Tilley WD 2008 Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology 110 236-243. (doi:10.1016/j.jsbmb.2007.10.014)
18. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C & Gerald WL 2006 An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 3994-4008. (doi:10.1038/sj.onc.1209415)
19. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D et al. 2005 Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 4660-4671. (doi:10.1038/sj.onc.1208561)
20. Fels E 1944 Treatment of breast cancer with testosterone propionate. Journal of Clinical Endocrinology 4 121-125. (doi:10.1210/jcem-4-3-121)
21. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II et al. 1998 Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. International Journal of Cancer 78 766-774. (doi:10.1002/(SICI)1097- 0215(19981209)78:6〈766::AID-IJC15〉3.0.CO;2-L)
22. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL et al. 2009 Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clinical Cancer Research 15 2472-2478. (doi:10.1158/1078-0432. CCR-08-1763)
23. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F & Schulz KD 1991 Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Research 51 5722-5727.
24. Hackenberg R, Hawighorst T, Filmer A, Nia AH & Schulz KD 1993 Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Research and Treatment 25 217-224. (doi:10.1007/BF00689836)
25. Hall RE, Birrell SN, Tilley WD & Sutherland RL 1994 MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. European Journal of Cancer 30A 484-490. (doi:10.1016/0959-8049(94)90424-3)
26. Hardin C, Pommier R, Calhoun K, Muller P, Jackson T & Pommier S 2007 A new hormonal therapy for estrogen receptor-negative breast cancer. World Journal of Surgery 31 1041-1046. (doi:10.1007/s00268-007-0694-8)
27. 2-terminal interaction with the ligand binding domain of the androgen receptor. Journal of Biological Chemistry 275 22986-22994. (doi:10.1074/jbc.M002807200)
28. 2- and COOH-terminal interaction. Journal of Biological Chemistry 277 25631-25639. (doi:10.1074/jbc.M202809200)
29. Hubler TR, Denny WB, Valentine DL, Cheung-Flynn J, Smith DF & Scammell JG 2003 The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 144 2380-2387. (doi:10.1210/en.2003-0092)
30. Ikonen T, Palvimo JJ & Janne OA 1997 Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. Journal of Biological Chemistry 272 29821-29828. (doi:10.1074/jbc.272.47.29821)
31. Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, Snoek R, Dahlman-Wright K, Gustafsson JA, Shiu RP, Sheppard PC et al. 1999 Selective activation of the probasin androgen-responsive region by steroid hormones. Journal of Molecular Endocrinology 22 313-325. (doi:10.1677/jme.0.0220313)
32. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR & Wilson EM 1999 Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Molecular Endocrinology 13 440-454. (doi:10.1210/me.13.3.440)
33. Kong SL, Li G, Loh SL, Sung WK & Liu ET 2011 Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Molecular Systems Biology 7 526. (doi:10.1038/msb.2011.59)
34. Kraulis PJ 1991 MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. Journal of Applied Crystallography 24 946-950. (doi:10.1107/S0021889891004399)
35. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol JA 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750-2767. (doi:10.1172/JCI45014)
36. Magee JA, Chang LW, Stormo GD & Milbrandt J 2006 Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 147 590-598. (doi:10.1210/en.2005-1001)
37. Magklara A, Brown TJ & Diamandis EP 2002 Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. International Journal of Cancer 100 507-514. (doi:10.1002/ijc.10520)
38. Marcelli M, Tilley WD, Zoppi S, Griffin JE, Wilson JD & McPhaul MJ 1991 Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg- - - -Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function. Journal of Clinical Endocrinology and Metabolism 73 318-325. (doi:10.1210/jcem-73-2-318)
39. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A et al. 2000 Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. Journal of Biological Chemistry 275 26164-26171. (doi:10.1074/jbc.M004571200)
40. Merritt EA & Murray MEP 1994 Raster3D Version 2.0. A program for photorealistic molecular graphics. Acta Crystallographica D50 869-873.
41. Moore NL, Hickey TE, Butler LM & Tilley WD 2012 Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology 357 60-70. (doi:10.1016/j.mce.2011.09.019)
42. Naderi A & Hughes-Davies L 2008 A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10 542-548.
43. Naderi A & Liu J 2010 Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Letters 298 74-87. (doi:10.1016/j.canlet.2010.06.005)
44. Naderi A, Chia KM & Liu J 2011 Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Research 13 R36. (doi:10.1186/bcr2858)
45. Need EF, Scher HI, Peters AA, Moore NL, Cheong A, Ryan CJ, Wittert GA, Marshall VR, Tilley WD & Buchanan G 2009 A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 150 2674-2682. (doi:10.1210/en.2008-1181)
46. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS & Brown M 2011 Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20 119-131. (doi:10.1016/j.ccr.2011.05.026)
47. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, Carazo JM & Pascual-Montano A 2009 GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Research 37 W317-W322. (doi:10.1093/nar/gkp416)
48. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C & McKenna NJ 2009 GEMS (Gene, Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17β-estradiol in MCF-7 cells. Cancer Research 69 23-26. (doi:10.1158/0008-5472.CAN-08-3492)
49. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T & Rabe T 2002 Testosterone and 5α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecological Endocrinology 16 113-120.
50. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL et al. 2009 Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Research 69 6131-6140. (doi:10.1158/0008-5472.CAN-09-0452)
51. Poulin R, Baker D & Labrie F 1988 Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Research and Treatment 12 213-225. (doi:10.1007/BF01805942)
52. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG & Carroll JS 2011 Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal 30 3019-3027. (doi:10.1038/emboj.2011.216)
53. Sarkar G & Sommer SS 1990 The "megaprimer" method of site-directed mutagenesis. Biotechniques 8 404-407.
54. Steketee K, Ziel-van der Made AC, van der Korput HA, Houtsmuller AB & Trapman J 2004 A bioinformatics-based functional analysis shows that the specifically androgen-regulated gene SARG contains an active direct repeat androgen response element in the first intron. Journal of Molecular Endocrinology 33 477-491. (doi:10.1677/jme.1.01478)
55. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG et al. 2010 The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 4 35-41.
56. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al. 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS 102 15545-15550. (doi:10.1073/pnas.0506580102)
57. The Cooperative Breast Cancer Group 1961 Progress report: results of studies by the cooperative breast cancer group. Cancer Chemotherapy Reports 111 109-141.
58. Tilley WD, Marcelli M, Wilson JD & McPhaul MJ 1989 Characterization and expression of a cDNA encoding the human androgen receptor. PNAS 86 327-331. (doi:10.1073/pnas.86.1.327)
59. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW et al. 1998 Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Research 58 3237-3242.
60. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO & Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 173 534-540. (doi:10.1016/S0006-291X(05)80067-1)
61. Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC & Jansen M 2003 Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. Journal of Clinical Endocrinology and Metabolism 88 277-284. (doi:10.1210/jc.2002-020354)
62. Williams SP & Sigler PB 1998 Atomic structure of progesterone complexed with its receptor. Nature 393 392-396. (doi:10.1038/30775)
63. Yen PM, Liu Y, Palvimo JJ, Trifiro M, Whang J, Pinsky L, Janne OA & Chin WW 1997 Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription. Molecular Endocrinology 11 162-171. (doi:10.1210/me.11.2.162)